《新股消息》百奧賽圖-B(02315.HK)公開發售超購4.93倍 一手中籤率50%
百奧賽圖-B(02315.HK)公布招股結果,每股發售價定為25.22元,香港公開發售部分錄得超額認購約4.93倍。每手500股計,一手中籤率50%,要認購14手即7,000股才穩獲一手。該股將於明日(9月1日)掛牌。聯席保薦人為高盛及中金。
是次上市引入5名基石投資者,包括維科(香港)經貿、榮昌生物-B(09995.HK)、桂林三金(002275.SZ)旗下三金國際、QuantumPharm及北京興星股權投資合夥企業,合共認購1,547.85萬股公司股份,佔緊隨全球發售完成後已發行股本約3.9%。
公司上市料淨集資約4.71億元,約70%用於為核心產品的進一步臨床研發提供資金;約15%用於根據千鼠萬抗計劃為抗體藥物發現及開發提供資金;約10%用於其他管線產品的臨床前及臨床開發;約5%將用作營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.